Elan’s Board Unanimously Rejects Royalty Pharma’s Revised Offer – ValueWalk Premium
Elan Corporation

Elan’s Board Unanimously Rejects Royalty Pharma’s Revised Offer

Elan Corporation, plc (NYSE:ELN) today announced that its board of directors has rejected a revised bid from privately held investment firm Royalty Pharma.

Irish biotechnology firm Elan Corporation, plc (NYSE:ELN) said its board has rejected the offer from Royalty Pharma, through its subsidiary Echo Pharma Acquisition Ltd, to acquire all of the shares of Elan Corporation, plc (NYSE:ELN) for $13.00 plus up to an additional $2.50 per share in contingent voting rights (CVR).

SORRY!

This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.


X
Saved Articles
0